EP300 and plasma cell myeloma: The proliferation and survival of MM are dependent on the activity of CBP/p300, where CBP/p300 inhibition could lead to the direct suppression of IRF4 expression and concomitantly, IRF4 suppress the oncogenic transcription factor c-MYC, thus providing anti-myeloma effects [85].